Skip to main
OCS

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding is expected to see success due to its strong cash position of $278 million, which is expected to fund operations into the second half of 2029, and the company's focus on late-stage development programs Privosegtor and Licaminlimab, which have blockbuster potential in addressing optic neuropathies. However, risks to their target price include clinical trial failure, competition with other late-stage development candidates, commercialization risk, and financial risk, as the company will require additional capital for the development and potential commercialization of its product candidates.

Bears say

Oculis Holding is facing a negative outlook as its Phase III trials for OCS-01 eye drops in diabetic macular edema (DME) missed their primary and key secondary endpoints. Despite a strong balance sheet and promising late-stage programs, the company's decision to not pursue an FDA regulatory filing for OCS-01 in DME and redirect resources to other programs raises concerns about its ability to successfully bring new products to market. Additionally, while its Privosegtor program shows potential in the neuro-ophthalic market, it may face challenges in obtaining adequate payor access and reimbursement.

OCS has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 9 analysts, OCS has a Strong Buy consensus rating as of Aug 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.